HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mao, C.-s. Articles by Stavnezer, J. Search for Related Content PubMed PubMed Citation Articles by Mao, C.-s. Articles by Stavnezer, J.

Differential Regulation of Mouse Germline Ig 1 and Promoters by IL-4 and CD40¹

Department of Molecular Genetics, Program in Immunology and Virology, University of Massachusetts Medical School, Worcester MA 01655

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Before Ig class switching, RNA transcription through the specific S regions undergoing recombination is induced by cytokines and other activators that induce and direct switching. The resulting germline (GL) transcripts are essential for switch recombination. To understand the differential regulation of mouse IgG1 and IgE, we compared the promoters for GL 1 and transcripts. We addressed the question of why the promoter that regulates GL transcription is more responsive to IL-4 than the 1 promoter and also why GL transcription is more dependent on IL-4 than is 1 transcription. We found that the IL-4-responsive region of the GL promoter is more inducible than that of the 1 promoter, although each promoter contains a binding site for the IL-4-inducible transcription factor Stat6, located immediately adjacent to a binding site for a basic region leucine zipper (bZip) family protein. However, the arrangement and sequences of the sites differ between the and 1 promoters. The GL promoter binds Stat6 with a 10-fold higher affinity than does the 1 promoter. Furthermore, the bZip elements of the two promoters bind different transcription factors, as the GL promoter binds and is activated by AP-1, whereas the 1 promoter binds and is activated by activating transcription factor 2. C/EBP and C/EBP also bind the 1 bZip element, although they inhibit rather than activate transcription. However, inhibition of promoter activity by C/EBP does not require the bZip element and may instead occur via inhibiting the activity of NF-B.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Upon activation by Ag or mitogens, IgM⁺ B cells undergo Ig class switching, resulting in expression of a different heavy chain constant region (C_H) gene, or isotype while maintaining expression of the same variable region gene (reviewed in Refs. 1, 2, 3). Because the C_H region determines the Ab effector function, class switching allows the humoral immune response to adaptively respond to a variety of different infectious organisms. Class switching is mediated by DNA recombination occurring between switch (S) region sequences residing 5' to each C_H gene, except C (4, 5).

Numerous studies have established that transcription of unrearranged C_H genes occurs before switch recombination, producing what are termed germline (GL)³ or switch transcripts (reviewed in Ref. 2). Transcription initiates at an I exon located 5' to each S region and continues through the S region and C_H gene. Splicing removes the S region sequences and joins the I exon with the C_H exons. Deletions of various portions of the I exons and their upstream regulatory elements by gene targeting experiments have demonstrated that GL transcripts are required for switch recombination (6, 7, 8, 9, 10). However, the role of GL transcripts in directing class switch recombination is unknown.

In this manuscript, we examine mechanisms regulating differential expression of the GL transcripts required for IgG1 and IgE class switching in the mouse. IgG1 can bind and activate complement, binds the low-affinity FcRIII receptor on macrophages, neutrophils, mast cells and NK cells, and is protective against bacterial and viral infections (3). IgE binds to high-affinity receptors (FcRI) on mast cells and basophils and induces degranulation and cytokine production by these cells when engaged with Ag, helping to eliminate parasitic helminths (11). However, IgE causes allergic responses, and in industrial societies is often more dangerous than protective.

IgG1 and IgE are produced in response to T-dependent Ags, although IgG1 in much greater abundance than IgE. Both isotypes are produced during Th2 immune responses, as they are induced by the cytokine IL-4 (12, 13). Furthermore, T cell contact help, primarily mediated by CD40-CD40 ligand (L) interaction, is important for B cell activation, proliferation, and isotype switching during T-dependent immune responses (14, 15, 16). Ab to CD40 or CD40L synergizes with IL-4 to induce switching to IgG1 and IgE in cultured mouse splenic B cells (17, 18) and expression of certain IgG subclasses and IgE in cultured human B cells (19, 20). Although IL-4 induces both IgG1 and IgE, these isotypes differ in their dependence on IL-4. Switching to IgG1 is only partially reduced in T cell-dependent immune responses in IL-4-deficient mice, whereas IgE switching is undetectable or only weakly induced by long-term infection with parasites (21, 22, 23, 24).

IL-4 directs class switch recombination to IgG1 and IgE by inducing GL 1 and transcripts in activated B cells (25, 26, 27). CD40L or Ab to CD40 synergizes with IL-4 to further induce GL and mouse 1 transcripts in cultured mouse splenic B cells (28, 29, 30, 31, 32). In the absence of IL-4, CD40 signaling induces modest levels of GL 1 and transcripts, but 1 transcripts appear to be more inducible than transcripts (18, 31, 32).

In addition to evidence suggesting that the GL 1 transcripts are more inducible by CD40 signaling than are transcripts, cross-linking of surface Ig in vitro has been shown to induce the promoter for GL 1 transcripts (33) and anti-IgD conjugated with dextran (anti- dextran) has been shown to induce endogenous 1 transcripts (34). By contrast, induction of GL transcripts by IL-4 and LPS is inhibited by treatment of splenic B cells with anti- dextran (34).

Transient reporter gene assays have been used to examine the mechanism of transcriptional regulation of GL 1 and RNA by CD40L and IL-4. Similar to the endogenous transcripts, treatment with CD40L and IL-4 activates transcription from both promoters, and CD40L alone activates the mouse GL 1 promoter somewhat better than the promoter (35, 36, 37). In addition, the promoter can be induced by IL-4 alone, whereas the 1 promoter cannot be (33, 36, 38). Therefore, transcription of GL RNA appears to be more inducible by IL-4, but also more dependent on IL-4, than transcription of 1 RNA.

In this report, we compare the promoters for GL 1 and transcripts to understand the differential regulation of IgG1 and IgE expression. We address the question of why the GL promoter is more responsive to IL-4 than is the 1 promoter. The IL-4-responsive regions of the GL 1 and promoters are similar, each containing a binding site for the IL-4-inducible transcription factor Stat6, located immediately adjacent to a binding site for a basic region leucine zipper (bZip) family protein that is important for IL-4 induction. However, the placement of the two sites relative to each other and the sequences of the two elements differ (see Fig. 1, A and B). We ask whether the placement of the two elements or the different sequences of the elements are more important for differential regulation of the GL 1 and transcription. Our data also address the question of why the promoter is more dependent on IL-4 than is the 1 promoter.

View larger version (38K): [in this window] [in a new window]   FIGURE 1. The Stat6 and adjacent bZip factor binding sites in the mouse GL 1 and promoters contribute to differential regulation of the two promoters. Left, DNA sequences of the Stat6 and bZip elements in the reporter plasmids containing: A, wild-type sequences from the mouse GL 1 promoter -148/+202 (1Luc wt); B, GL promoter -162/+ 53 (Luc); C, mutant plasmid (1Non-ov), generated by inserting nucleotides TGAA after the original TGAA to eliminate the overlap between the Stat6 and bZip sites in the 1 promoter; D, mutant plasmid 1Inv inverts the positions of the nonoverlapped Stat6 and bZip sites to resemble their organization in the promoter. Plasmid luc(1); E, mutant plasmid Luc (1) contains the promoter backbone with the 1(Stat6 + bZip) elements; F, mutant plasmid 1Luc () contains the 1 promoter backbone with the (Stat6 + AP-1) sites; G, mutant plasmid 1Luc(B) contains the 1 backbone and Stat6 site along with the AP-1 site; H, mutant plasmid 1Luc(S) contains the 1 promoter backbone and bZip element along with the Stat6 site. Right, Results of transient transfection assays in which the reporter plasmids were transfected into the mouse B cell line M12.4.1. Transfected cells were aliquoted and cultured for 12 h in medium alone or together with IL-4 (4000 U/ml), CD40L supernatant (25%), control supernatant for CD40L (Ctrl S.), or their combination. Luciferase activity in the transfected cells was assayed and presented as light units (middle), and the ratio of the activities of treated cells relative to untreated cells in each group is calculated as fold induction (right). The means + SEM from three independent experiments are presented.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

Splenic B cells were isolated from 8- to 10-wk-old BALB/c or 129 x C57BL/6 mice by depletion of T cells as described previously (39). Mouse splenic B cells and the B cell lines M12.4.1 and A20.3 were maintained at 37°C in 5% CO₂ incubator in RPMI 1640 medium (BioWhittaker, Walkersville, MD) supplemented with 10% FCS (HyClone, Logan, UT or BioWhittaker), 0.1 mM nonessential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml kanamycin, 1 mM sodium pyruvate, 2 mM L-glutamine (all from Life Technologies, Grand Island, NY), and 50 µM 2-ME (Sigma, St. Louis, MO).

Stimulatory reagents

Recombinant mouse IL-4 (a gift from W. E. Paul, National Institutes of Health, Bethesda, MD) was a culture supernatant prepared from insect cells infected with recombinant baculoviruses (40). The source of CD40L was a supernatant containing CD40L-CD8 fusion protein secreted from stably transfected J558L myeloma cells cultured in complement RPMI 1640 medium-10% FCS (15, 35). Supernatant from nontransfected J558L cell cultures, used at the same concentration, was the control supernatant. The amounts used are indicated in the figure legends. Anti--dextran (3 ng/ml; gift from C. Snapper, Uniformed Services University of the Health Sciences, Bethesda, MD) or LPS (50 µg/ml, 055:B5; Sigma) dissolved in RPMI 1640 medium was added to splenic B cell cultures at the initiation of the culture.

Oligonucleotides

The following oligonucleotide sequences (upper strand) were used for DNA probes or competitor fragments in EMSAs. Lower case letters indicate mutated nucleotides. Binding sites for transcription factors C/EBP, CREB/activating transcription factor (ATF), or AP-1 are underlined. Stat6 binding sites are in bold face: 1(S + B), 5'-ACACATTCACATGAAGTAATCTAAG-3'; 1Stat6, 5'-ACACATTCACATGAAGagtTCTAAG-3'; 1bZip, 5'-ACACAggttCATGAAGTAATCTAAG-3'; (S+B), 5'-TGCCTTAGTCAACTTCCCAAGAACAGA-3'; AP-1 consensus (CS), 5'-AGCTTGGTGACTCATCCG-3'; C/EBP CS, 5'-TGCAGATTGCGCAATCTGCA-3'; CREB/ATF CS, 5'-AGAGATTGCCTGACGTCAGAGACT-3'; Stat6, 5'-ACTTCCCAAGAACA-3'; Bcl6 CS, 5'-GAAAATTCCTAGAAAGCATA-3'; octamer-binding protein (Oct), 5'-TGTCGAATGCAAATCACTAGAA-3'.

Reporter plasmids

The luciferase reporter plasmid 1Luc (=Luc4) containing the mouse GL 1-148/+202 promoter segment and the luciferase reporter plasmid (Luc) containing the mouse GL promoter -162/+53 segment have been described previously (33, 38). For construction of plasmid 1Non-ov, 1Inv, and 1Luc(), DNA fragments were amplified by PCR with 1Luc as template with forward primer: NonF, 5'-CAGGGTACCGCCTCACCCTCACCCACACATTCACATGAATGAAGTAATCTAAGTCAGGTTTG-3'; InvF, 5'-CAGGGTACCGCCTCACCCTCACCCACACATGAAGTAATTTCACATGAACTAAGTCAGGTTTG-3'; g1eF, 5'-CAGGGTACCGCCTCACCCTCACCCACACATTAGTCAACTTCCCAAGAACTAAGTCAGGTTT-3'. The KpnI sites used for cloning are underlined. One reverse primer was used: g1R, 5'-CAAGCTgAGATCTGGAAG-3' (BglII site is underlined). The amplified fragments were digested with KpnI and BglII and cloned into the pXP2 luciferase vector (41) digested with the same enzymes. To construct the reporter plasmid 1Luc(B) and 1Luc(S), DNA fragments were amplified from plasmid 1Inv with g1R as the reverse primer paired with one of the following forward primer: 1Luc(B)F, 5'-CAGGGTACCGCCTCACCCTCACCCACACAttagtcaaTTCACATGAACTAAGTC-3' or 1Luc(eS)F, 5'-CAGGGTACCGCCTCACCCTCACCCACACATGAAGTAATttcccaagaaCTAAGTC3'. The lowercase letters represent the AP-1 site sequence (in g1eBF) or STAT6 site (in g1eSF). The amplified fragments were digested with KpnI and BglII and inserted into pXP2. Similarly, to construct the reporter plasmid Luc(1), a DNA fragment was amplified from Luc template with a primer pair as follows: eg1F, 5'-GGCAGGCCTCACCTGAGACCcCACTGTGCCTTCACATGAAGTAATCAGAATCAAAAGGGAAC-3' (StuI site sequence is underlined) and eR, 5'-CCAAGCTgAGATCTGTGC (BglII site sequence is underlined). The amplified fragments were digested with StuI-BglII and inserted into Luc, digested with the same enzymes.

Other mutated reporter plasmids were generated with the QuickChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s protocol. Three basepair replacement mutations in the bZip site of the 1 promoter were obtained using the mutagenic oligonucleotide mbZipF: 5'-ACACATTCACATGAAGagtTCTAAGTCAGGTTTG-3'. Only the forward primer sequence is shown. The 1 promoter containing three mutated NF-B sites, m3B, was created by sequentially replacing each of the three NF-B sites with the following mutagenic oligonucleotides: mB-1F, 5'-CTAAGTCAGGTTTtGACTCgagCTCACCCTCTGAC-3'; mB-2F, 5'- CCTCTGACACAGAActgCagAGAATGAAGGGGAAC-3'; mB-3F, 5'-CCCCAGAATGAAttctAACCCTGTCAGGAAATG-3'. The underlined sequences represent individual NF-B sites, and the lowercase letters represent the mutagenic nucleotides. The reporter plasmid 1Luc-mbZip-m3B, containing mutations in both the bZip site and 3-B sites was similarly generated with the primer mbZip on the m3B 1 reporter plasmid. DNA sequences of the wild-type and mutant promoters in the reporter plasmids were verified by sequencing the entire 1 or sequence and flanking vector sequences. Luciferase reporter plasmids containing a minimal alkaline phosphatase promoter linked upstream with (E4APLuc) or without (APLuc) four copies of a C/EBP binding site (42) were provided by C. Cooper (University of Massachusetts Medical School, Worcester MA).

Expression plasmids

The eukaryotic expression plasmids, cloned in pcDNA3, expressing CEBP, C/EBP, c-Fos, JunB, or c-Jun were described previously (32). Expression plasmids pcDNA3-ATF2 and the dominant-negative pcDNA3-ATF2dn were provided by Phyllis LuValle (University of Calgary, AB, Canada) (43). The expression plasmid for mouse ATF4 was generated from cDNA obtained from I.29µ B cell RNA by RT-PCR with ATF4 forward primer 5'-ATGGGATCCACAACCATGACCGAGATGAG-3', and reverse primer 5'-GAGGAATTCACAAAGCACCTGACTAC-3'. The underlined letters represent BamHI (in forward primer) or EcoRI (in reverse primer) sites. The amplified DNA fragment was digested with BamHI and EcoRI and inserted into pcDNA3, cut by the same enzymes. DNA sequencing confirmed that the cloned gene has exactly the same sequence as the mouse ATF4 gene in GenBank (accession number M94087) (44). The bZip domain of C/EBP (amino acids 187–296) was amplified by PCR from the mouse C/EBP expression plasmid with the upstream primer 5'-AGGAATTCCACCATGGCGCCCGGCACGCCGAG-3' and downstream primer 5'-CGCGCCGCGCTAGCAGTG-3'. The underlined nucleotides indicate the EcoRI and NheI restriction sites. The resulting product was digested by EcoRI and NheI and ligated into pcDNA3, cut by EcoRI and XbaI.

Transient transfection assays

All of the plasmids used for transient transfection were prepared using Qiagen kits (Valencia, CA). Mouse M12.4.1 or A20.3 cells mixed with 30 µg of reporter plasmid and the indicated amount of expression plasmids, along with 1 µg of -galactosidase (-gal) reporter plasmid pPGK-gal (Ref. 45 ; except in the experiment shown in Fig. 1) in 1 ml of RPMI 1640 were electroporated at 1250 µF/300 V and split into equal fractions. Aliquoted cells were left untreated or treated for 12 h with IL-4, CD40L, or the phorbol ester PMA, as indicated, in complete RPMI 1640 medium. Cell lysates and luciferase assays were prepared as described previously (36). The -gal assays were performed as described on the samples that were not treated with inducers (46). Luciferase values were normalized relative to the internal -gal activity.

EMSAs

Nuclear extracts of splenic B cells and of M12.4.1 B cells were prepared as described previously (36). DNA binding reactions were performed at room temperature for 15–20 min in 15-µl reaction volumes containing nuclear extracts from splenic B cells or from M12.4.1 B cells (3 µg), 4 nmol of ³²P-end-labeled DNA probe, 2 µg of poly(dI-dC), 10 mM Tris-HCl (pH 7.6), 1 mM MgCl₂, 100 mM NaCl, 1.2% (v/v) glycerol, 5 mM KCl, 0.1 mM EDTA, and 1 mM DTT. For DNA competition experiments, a 100-fold molar excess (unless otherwise indicated) of unlabeled competitor oligonucleotides relative to the labeled probe was incubated in the binding mixture for 20 min before addition of the ³²P-labeled probe. For Ab supershift experiments, 1 µl of the indicated specific Ab was added to the binding reaction. The binding reaction mixtures were electrophoresed in 5% native polyacrylamide gels with 0.5x Tris-borate-EDTA buffer, followed by autoradiography. Abs against mouse CREB-1 (sc-186X, cross reactive with ATF1 and CREM1, as indicated by the manufacturer), ATF4 (CREB-2; sc-200X), ATF2 (sc-187X), ATF3 (sc-188X), C/EBP (sc-061X), C/EBP (sc-150X), C/EBP (sc-7659X), and STAT6 (sc-981X) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Western blotting

Thirty micrograms of nuclear protein from splenic B cells, M12.4.1 or BclI-3B3 was fractionated on 15% reducing SDS-polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were first incubated with the Ab against ATF2 or C/EBP in TBST buffer (20 mM Tris-HCl (pH 7.5), 137 mM NaCl, and 0.05% Tween 20) in the presence of 5% nonfat milk powder. Upon washing with TBST, blots were incubated with HRP-conjugated second Ab. The Abs and HRP conjugate were purchased from Santa Cruz Biotechnology. The immunoreactive bands were revealed on film by using the SuperSignal chemiluminescent substrate (Pierce, Rockford, IL) according to the manufacturer’s instructions.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Comparative activities of the IL-4 response elements of the GL and 1 promoters

The IL-4-responsive region of the mouse GL promoter has been studied by a combination of reporter gene assays and EMSAs. These experiments have demonstrated that two adjacent sequence elements are required for IL-4 induction of the mouse GL promoter, a binding site for Stat6 and a site for AP-1 (Fos and Jun) transcription factors (consensus site (CS), TGAGTCA) (32, 36, 38 , and 47). Fig. 1B presents the sequence of the IL-4-responsive region of the GL promoter. If either the Stat6 or AP-1 element is mutated, IL-4 induction is completely eliminated (32, 36, 38). Furthermore, cotransfection of various AP-1 proteins along with the reporter plasmid into the I.29µ B cell line greatly activates the promoter in IL-4-treated cells (32). Although the AP-1 site can bind bacterially produced recombinant C/EBP(NF-IL-6) and C/EBP(Ig/EBP), this site binds AP-1 but not C/EBP when EMSAs are performed with B cell nuclear extracts. Furthermore, C/EBP proteins do not activate transcription of the mouse GL promoter (32). Both AP-1 and C/EBP are bZip transcription factors, a family that also includes ATF/CREB proteins. The three different families of bZip proteins, AP-1, C/EBP, and ATF, have related but not identical binding sites, although they often are found to bind each other’s sites with lower affinity (48, 49)

The elements of the GL 1 promoter that are required for IL-4 responsiveness have not been defined, although a Stat6 binding element has been identified within the IL-4-responsive region (33, 50, 51, 52). Overlapping the Stat6 site is an element, TGAAGTAAT, that binds C/EBP and C/EBP in B cell nuclear extracts, as assessed by Ab supershift assays (52). Mutations created within the C/EBP site suggested its importance for promoter expression, although because of the large numbers of nucleotides mutated, the data were not definitive (33). Furthermore, cotransfection experiments to assess whether C/EBP proteins activate the GL 1 promoter have not been reported. Thus, it is unknown whether this element is required for promoter expression and for IL-4 induction, nor is it known which proteins might activate transcription at this site. Fig. 1A shows the sequence of the GL 1 promoter region containing the Stat6 and C/EBP elements. To indicate the possibility that other proteins may function via the latter element, we label this element bZip.

To determine whether the differences in the Stat6 and bZip elements of these promoters affect induction of the GL 1 and transcripts by IL-4 and CD40 signaling, we systematically interchanged the consensus elements of this region between the two promoters. The activity of each of the reporter plasmids was tested by transient reporter gene assays in the B cell line M12.4.1. This cell line was chosen because it supports CD40L-inducible expression of both of these promoters, and IL-4-inducible expression of the GL promoter. However, the level of IL-4 induction of the GL 1 promoter in this cell line is very low. The IL-4-responsive region of the 1 promoter was defined previously in two B cell lines, L10A6.2 and A20.3, in which IL-4 synergizes with phorbol ester to induce the promoter (Fig. 2B and Ref. 33). Phorbol ester delivers a signal that partially mimics the signals produced by cross-linking surface Ig. Ab against surface Ig also synergizes with IL-4 to activate the GL 1 promoter (33). By contrast, in M12.4.1 cells, the 1 promoter is poorly inducible by phorbol ester or by the combination of phorbol ester and IL-4 (Fig. 2A). We could not use A20.3 because the GL promoter is not expressed well in these cells, nor could we use L10A6.2 because the 1 promoter is not inducible by CD40L in these cells (data not shown). Presumably, the GL and 1 promoters respond differently among cell lines because of differences in receptors, signaling molecules, or transcription factors, and different responses between cell lines are not unique to these promoters. Because of this, it is important to use the same cell line for comparative studies of the two promoters.

View larger version (43K): [in this window] [in a new window]   FIGURE 2. Reporter gene assays testing induction of the GL 1 -148/+202 promoter in three B cell lines and effect of mutation of the bZip element. Reporter plasmids containing wild-type (1Luc) or bZip-mutated promoter (1Luc-mbZip; sequence shown in C) were transfected into M12.4.1 (A) or A20.3 (B) cells, as indicted. Aliquots of the transfected cells were cultured with medium alone or treated with IL-4 (1000 U/ml), CD40L supernatant (20%), PMA (50 ng/ml), or IL-4 + CD40L for 12 h before harvesting. The luciferase activities were determined and normalized to the -gal activity of the internal control reporter plasmid. The data presented are the means + SEM from three transfection experiments. C, DNA sequences of the IL-4/CD40L-responsive regions of the wild-type mouse GL 1 promoter (1Luc), mutant ATF site promoter (1Luc-mbZip), three-B site mutation (1Luc-m3B), or all four mutations (1Luc-mbZip-m3B). The boxed sequences represent the Stat6 sites. The wild-type ATF-binding sites and NF-B sites are underlined with solid lines, and mutated sites with dotted lines. The lowercase bold letters indicate mutated nucleotides.

The wild-type GL promoter -162/+53 segment, assayed identically, is more inducible by IL-4, 5-fold by IL-4 alone, but less inducible by CD40L alone (2-fold; Fig. 1B and Ref. 36). The combination is synergistic, giving a 32-fold increase relative to the medium control. However, even in the presence of IL-4 + CD40L, the overall luciferase activity obtained from the GL promoter is less than that of the 1 promoter (Fig. 1B, middle).

We hypothesized that the differences in the Stat6 and bZip elements of these two promoters might affect the different levels of activity and the differential responsiveness of the 1 and promoters to CD40L and IL-4. There are three obvious differences between these two promoters in this region. The Stat6 and bZip elements differ in their positions relative to each other and are overlapping in the 1 promoter and separate in the promoter. In addition, the sequences of both the Stat6 and bZip elements of the two promoters differ.

To make the subsequent experiments easier, we first tested whether separating the 1 bZip and Stat6 elements so that they would not overlap would affect promoter activity (Fig. 1C). This change has a minimal effect on the promoter activity, although it reduces the responsiveness to the combination of IL-4 and CD40L. We next tested whether responsiveness of the 1 promoter would be altered if the positions of the Stat6 and bZip elements were exchanged relative to each so that now the Stat6 site is located 3' to the bZip site. As shown in Fig. 1D, this had only a small effect, indicating that the difference between the 1 and promoter is not attributable to the different relative positions of the Stat6 and bZip elements.

These data suggested that the specific sequences of the Stat6 and/or bZip elements are likely to be important in the differential responsiveness. We tested this hypothesis by replacing the elements with the sequences of the 1 elements and vice-versa. Fig. 1E shows that replacing the Stat6 and AP-1 sites of the promoter with the two 1 elements results in a promoter with very little activity. By contrast, substituting the two elements into the 1 promoter results in a promoter that is highly inducible by IL-4 alone (18-fold) and 4-fold by CD40L alone, with the combination giving a total induction of 47-fold. Also, the overall activity of the chimeric promoter is 10 times greater than either wild-type promoter. Altogether, these data indicate that the IL-4-responsive region of the promoter is responsible for the greater inducibility of the promoter and that this is attributable to the particular sequences of this region. Furthermore, the data suggest that the remainder of the 1 promoter has additional elements that provide a greater overall level of activity than that of the GL promoter. This result is consistent with data indicating that the promoter is more dependent on IL-4 than the 1 promoter, whereas the 1 promoter can also be activated by additional transcription factors that do not depend on IL-4 signaling.

We next asked whether the Stat6 and AP-1 binding sites are both required for this increased responsiveness by replacing only the 1 bZip site (Fig. 1G) or only the 1 Stat6 site (Fig. 1H). It can be seen that both elements contribute to the increased responsiveness, as neither of these single-element replacements is as active as the promoter containing both elements, although each is slightly more inducible by IL-4 than the wild-type 1 promoter.

Relative binding affinities of the and 1 Stat6 elements

One possible explanation for the greater IL-4 inducibility of the GL promoter relative to the 1 promoter is that the Stat6 element has a higher affinity for Stat6 than the 1 element. Although both Stat6 elements match the consensus binding site, TTCN₄GAA, they differ in the central and flanking nucleotides. The relative affinity of the and 1 Stat6 sites was examined by performing competition EMSAs with a double-stranded oligonucleotide containing the (Stat6 + AP-1) segment as the probe (Fig. 3A). Competition was performed with the identical oligonucleotide, or with other oligonucleotides containing the 1(Stat6 + bZip) elements, or chimeric oligonucleotides containing the Stat6 + 1 bZip sites and vice versa (see Fig. 3A). Fig. 3B demonstrates that the (Stat6 + AP-1) probe binds an IL-4 inducible factor in M12.4.1 nuclear extracts, shown by Ab supershift assays to be Stat6 (36), and that this binding is competed by the unlabeled probe (lanes 2–7). The 1(Stat6 + bZip) oligonucleotide competes poorly (lanes 9–12). Use of chimeric oligonucleotides demonstrates that the Stat6 element is responsible for the differing abilities to compete and that spacer nucleotides account for the difference (lanes 13–17 and 18–22). Quantitation of the results by densitometry demonstrates that by this assay the Stat6 element has an 10-fold greater affinity for Stat6 than does the 1 element (Fig. 3C). The dramatic influence of the sequence of the spacer nucleotides on binding affinity is consistent with the recent report of Ehret et al. (53). In fact, according to this study, the GL Stat6 site is nearly an optimal binding site for Stat6. The higher affinity for Stat6 is consistent with the greater responsiveness of the GL promoter than the 1 promoter to IL-4.

View larger version (43K): [in this window] [in a new window]   FIGURE 3. Competition EMSAs demonstrating that the GL Stat6 element binds Stat6 with higher affinity than the GL 1 element. A, DNA sequences of the oligonucleotides used. Stat6 binding sites are underlined. Oligos (B + S) and 1(S + B) are derived from wild-type mouse GL promoter (-124/-97) and 1 promoter (-125/-103), respectively, and contain both the bZip and Stat6 sites. Oligo S+1B is the -125/-103 1 promoter segment with two nucleotide changes that convert the Stat6 element to the Stat6 element. Oligo B+1S is the promoter -124/-97 segment with two nucleotide changes converting the Stat6 element to the 1 Stat6 element. B, Competition EMSAs with the (B+S) oligo as labeled probe and competing with the indicated oligos. Nuclear extracts from M12.4.1 cells, untreated (lane 2) or treated with IL-4 for 12 h (lanes 3–22) were preincubated with the indicated molar excess of unlabeled competitor oligos as described in Materials and Methods. Lane 1 contains probe alone. C, Arbitrary densitometries of Stat6 complex from B shows the percent binding inhibition by competitors, setting the density in the absence of competition at 100.

Effect of the 1 bZip element on transcriptional activity

To determine whether the bZip element is important for expression of the 1 promoter, a mutation was created in the bZip element which does not disrupt the Stat6 binding site, as shown by competition EMSA (data not shown). Fig. 2C shows the sequence of the mutated promoter (1Luc-mbZip). This reporter plasmid was tested in comparison to the wild-type 1 promoter by transient transfection into two B cell lines (Fig. 2). The bZip mutation reduces activity of the promoter by 2.2-fold in M12.4.1 and by 5-fold in A20.3 cells. Although the overall level of promoter activity is reduced, the bZip element does not appear to be essential for induction by CD40L, CD40L + IL-4, or by phorbol ester. Thus, the bZip site of the 1 promoter does not play the same role as the AP-1 site of the GL promoter, in which it has been shown to be essential for both IL-4 inducibility and overall promoter activity in both M12.4.1 and I.29µ B cells (32, 38).

The 1 bZip element binds ATF and C/EBP proteins in B cell nuclear extracts

It is clear from data shown in both Figs. 1 and 2 that the role of the bZip element of the 1 promoter differs from the AP-1 site of the promoter. To explain this difference, it is important to identify the proteins that bind this site in B cell nuclear extracts. It has previously been shown that the 1 bZip site binds C/EBP and C/EBP (52). To confirm this result and to determine whether additional proteins may also bind, we performed a series of competition EMSAs using the 1(Stat6 + bZip) probe shown in Fig. 3A. The EMSA results shown in Fig. 4A demonstrate that at least six specific complexes form with this probe using nuclear extracts from unstimulated M12.4.1 cells. Stimulation of cells with LPS or CD40L does not change the complexes formed (Fig. 5A). Addition of 100-fold excess of unlabeled probe (Fig. 4A, lane 5) or an oligonucleotide containing the 1 bZip site (and a mutated Stat6 site, lane 3) greatly inhibits five of the six complexes. The 1 Stat6 (+mutated bZip element) oligo does not compete (lane 4), nor does the (Stat6 + AP-1) oligo (lane 6). Competition with an oligo having the consensus binding site for ATF/CREB (TGACGTCA) eliminates five of the complexes (lane 8), and competition with an oligo having the consensus C/EBP site (TTGCGCAA) competes well with complexes 2, 4 and 6 (lane 9). Oligos containing consensus elements for AP-1 (TGACTCA), Stat6, and Bcl6 do not compete (lanes 7, 10, and 11).

View larger version (89K): [in this window] [in a new window]   FIGURE 4. Competition and supershift EMSAs demonstrate that the bZip element of the mouse GL 1 promoter binds ATF/CREB and C/EBP proteins. Nuclear extracts from unstimulated M12.4.1 (A and C) or splenic B cells treated with CD40L for 24 h (B and D) were incubated with 32P-labeled 1(S+B) probe. Competition EMSAs (A and B) were performed with 100-fold molar excess of the following unlabeled oligonucleotides: lane 3, unlabeled 1 bZip oligo; lane 4, 1Stat6 oligo; lane 5, 1(bZip+Stat6) oligo; lane 6, (AP-1 + Stat6) oligo; lane 7, AP-1 CS site; lane 8, CREB/ATF consensus; lane 9, C/EBP consensus; lane 10, Stat6 consensus site; and lane 11, Bcl-6 consensus site. In Ab supershift assays (C and D), 1 µl of the indicated specific Ab was added before addition of the labeled probe. CREB1 Ab also reacts with ATF1. Supershifted complexes are indicated by open arrows. The proteins identified in the complexes are indicated at the right of C and D.

View larger version (46K): [in this window] [in a new window]   FIGURE 5. EMSAs to examine induction of ATF/CREB and C/EBP binding activities in nuclear extracts from M12.4.1 (A) and splenic B cells (B). Cells were stimulated for 24 h as indicated and as described in Materials and Methods. Three micrograms of nuclear extracts was incubated with the 32P-labeled 1(S+B) probe. Oct 1 binding with the same nuclear extracts is shown below each lane. C, Western blots to examine levels of ATF2 and C/EBP in nuclear extracts (30 µg) from splenic B cells stimulated as indicated for 24 h.

Ab supershift EMSAs were performed to confirm the binding of ATF/CREB and C/EBP proteins and to identify the specific proteins that bind. Ab to ATF2 supershifts the major complex 1 formed with extracts from both M12.4.1- and CD40L-treated splenic B cells, although in splenic B cell extracts, an additional complex 1b is not affected (Fig. 4, C and D, lane 4). In addition, ATF2 Ab appears to partially inhibit complex 2. ATF-4 Ab forms a weak supershifted complex with M12.4.1 extracts but not with splenic B cell extracts (lane 3), but no other ATF/CREB Ab has an effect. Ab for C/EBP supershifts complex 6 formed with M12.4.1 extracts and probably also with splenic extracts (lane 7). Ab to C/EBP inhibits complexes 2 and 6 formed with both extracts (lane 8). These data are consistent with previous published data indicating that C/EBP and C/EBP form multiple complexes with the GL 1 promoter (52), but in addition indicate that ATF2 forms the major complex 1 that binds the 1 bZip site. Complex 1 could consist of ATF2 homodimers or a heterodimer with another protein, although no other Ab we tested affects this complex. Although we failed to identify the proteins in complex 1b detected with splenic B cell extracts, it may contain a member of the ATF/CREB family, because it is competed by the oligo containing the consensus ATF/CREB element (Fig. 4B, lane 8).

ATF2 binding activity is inducible in splenic B cells

The finding that ATF2 binding activity is not inducible by LPS or CD40L in nuclear extracts from M12.4.1 or A20.3 cells (Fig. 5A and data not shown) is consistent with the finding that mutation of the bZip element in the reporter assays reduces overall expression but not inducibility in these cells (Fig. 2). However, because both of these cell lines are comparable to activated B cells, unlike freshly isolated splenic B cells, which mostly consist of resting B cells, we wished to determine whether ATF2 binding activity would be induced in splenic B cells by reagents that stimulate IgG1 switching. Splenic B cells were treated for 24 h with LPS, IL-4, CD40L, or anti-IgD conjugated with dextran (anti- dextran). As shown in Fig. 5B, treatment with each of these reagents, except IL-4, induces ATF2 binding (complex 1) and also complex 1b. However, C/EBP or C/EBP binding activities are not induced. This experiment was performed three times with similar results. As expected, IL-4 induces binding of Stat6. The binding activity of Oct 1 in these extracts is shown below as a control for extract quality and loading. The finding that ATF2 binding activity is induced by 24 h of treatment of splenic B cells with LPS or with anti- dextran is consistent with results reported by Feuerstein et al. (54).

To attempt to determine whether the increase in binding activity of ATF2 is attributable to an increase in protein levels, we examined the levels of ATF2 in splenic B cell nuclear extracts by Western blotting (Fig. 5C). Although freshly isolated splenic B cells do not have ATF2 binding activity, they do show constitutive levels of protein. Furthermore, the 3- to 6-fold induction of ATF2 protein levels observed by Western blotting in cells treated with LPS, anti- dextran, or CD40L is not nearly as great as the induction of binding activity shown by EMSA. These data suggest that increased binding activity is not primarily attributable to an increase in ATF2 levels. By contrast, C/EBP protein levels are nearly invariant (Fig. 5C).

Overexpression of ATF2 activates the GL 1 promoter, whereas overexpression of C/EBP and C/EBP inhibits the promoter

To determine whether ATF2 activates the GL 1 promoter when it binds the bZip site, we tested the effect of cotransfection of an expression plasmid for ATF2 along with GL 1 reporter plasmids into M12.4.1 and A20.3 cells. Two 1 reporter plasmids, containing either the wild-type sequence or the mutated bZip element, were tested. Overexpression of ATF2 increases the activity of the GL 1 promoter by about 2-fold in both M12.4.1 and A20.3 cells, and this induction depends on the bZip element (Fig. 6, A and B). We also tested the effect of overexpression of a dominant-negative form of ATF2, which lacks the transactivation domain (43), and found it inhibits the wild-type promoter but has no effect on the mbZip promoter. These data demonstrate that ATF2 activates the GL 1 promoter and that this most likely occurs via the binding of ATF2 to the bZip site.

View larger version (48K): [in this window] [in a new window]   FIGURE 6. Overexpression of ATF2 activates mouse GL 1 promoter via the bZip site and overexpression of C/EBP or C/EBP inhibit the promoter, but not via the bZip site. M12.4.1 (A) or A20.3 (B) cells were cotransfected with expression plasmids for ATF2, dominant-negative ATF2, or ATF4, as indicated (4 µg), and the luciferase reporter plasmid 1Luc containing the wild-type or mbZip mouse GL 1 promoters. Aliquots of the transfected cells were cultured with medium alone or treated with the indicated inducers for 12 h. Luciferase activity was normalized to -gal activity. C, Reporter plasmids containing wild-type or mbZip 1 promoters were transfected into M12.4.1 cells along with 4 µg of each of the expression plasmids for C/EBP, C/EBP or empty expression vector. Aliquots of transfected cells were treated as indicated. Mean light units normalized to -gal activity plus SEMs from three transfection experiments are presented. Results presented are the means of the ratios of luciferase activity (normalized to -gal) from cells cotransfected with expression plasmid for C/EBP to activity from cells transfected with empty vector pcDNA3. D, M12.4.1 B cells were transfected with expression plasmids for C/EBP or the empty vector pcDNA3 (8 µg for each), along with the luciferase reporter plasmid E4APLuc containing four copies of the IgH enhancer µE1 C/EBP binding site or with the empty reporter plasmid APLuc as indicated (42 ).

Finally, we tested the effect of overexpression of C/EBP and C/EBP on activity of the wild-type and mbZip reporter plasmids. As shown in Fig. 6C, both C/EBP and C/EBP inhibit reporter activity from plasmids containing either the wild-type or mbZip promoters in M12.4.1. These results indicate that both C/EBP proteins inhibit rather than stimulate activity of the GL 1 promoter, and that this inhibition does not require the bZip element. However, C/EBP and C/EBP do not behave identically, as C/EBP inhibits induction by CD40L in addition to reducing the overall level of activity, whereas C/EBP does not eliminate induction. These results are surprising because although C/EBP previously has been shown to inhibit transcription, C/EBP is generally found to be a transcriptional activator (55). Furthermore, although these proteins bind the bZip site in the 1 promoter, data in Fig. 6C indicate they do not require this site for their inhibitory activity. Note that the C/EBP expression plasmid we used is able to activate transcription on a reporter plasmid regulated by four tandem C/EBP binding sites (Fig. 6D).

Interaction of C/EBP and NF-B

The ATF2 binding site is important for expression of the GL 1 promoter, but it does not contribute to inducibility of the promoter by CD40L, anti-IgM, PMA, or the combination of CD40L and IL-4 in M12.4.1 and A20.3 cells (Fig. 2). The three NF-B sites of the promoter have been shown to be important for CD40L induction in M12.4.1 cells (35). To attempt to determine the relative importance of the NF-B and ATF binding sites for CD40L and PMA induction and promoter expression, we compared the effect of mutations of these sites in reporter assays in M12.4 and A20.3 cells. Fig. 2A shows the mutations tested and Fig. 7 presents the results of the reporter assays. The data demonstrate that mutation of all three B sites eliminates CD40L induction in M12.4.1 cells (Fig. 7A) and IL-4 induction in A20.3 cells (Fig. 7B) and greatly reduces the overall level of expression. The combination of the bZip mutation and the three B site mutations further reduces activity by about 2-fold in M12.4.1 cells. It is clear that the B sites of the 1 promoter are essential for both overall activity and for CD40L and IL-4 induction, whereas the bZip site is somewhat less important. Because ATF2 is inducible in splenic B cells, it is likely that the bZip site also contributes to induction by CD40L, LPS, and B cell receptor cross-linking in splenic B cells.

View larger version (21K): [in this window] [in a new window]   FIGURE 7. Effect of mutation of the bZip and NF-B binding sites on GL 1 promoter activity. A, M12.4.1 B cells were transfected with the indicated reporter plasmids and divided into two aliquots that were cultured for 12 h in the presence or absence of CD40L and assayed for luciferase activity, as described for Fig. 2. B, A20.3 B cells were transfected with the indicated reporter plasmids and divided into two aliquots that were cultured for 12 h in the presence or absence of PMA ± IL-4 and assayed for luciferase activity, as described for Fig. 2.

View larger version (29K): [in this window] [in a new window]   FIGURE 8. Cotransfection of expression plasmids for C/EBP, C/EBPbZip, C/EBP, and NF-B demonstrate that C/EBP inhibits activation of the GL 1 promoter by NF-B. A, Indicated amounts (µg) of expression plasmids for C/EBP, C/EBP, and NF-B (1 µg each of p50 and RelA), along with the control plasmid pPGKgal, were cotransfected with the wild-type or mutated GL 1 reporter plasmids or empty (pXP2) reporter into M12.4.1 cells. The total amount of DNA in each transfection was kept constant by addition of pcDNA3. Transfected cells were cultured for 12 h without addition of any activators before harvesting. Data are from three dependent transfections and expressed as light units after normalization to the activity of -gal. B, Forty micrograms of expression plasmids for C/EBP and C/EBPbZip and 2 µg of NF-B(p50/RelA) (1 µg for each), as well as control reporter plasmid pPGK-gal, were cotransfected with the indicated reporter plasmids and assayed as in A.

In conclusion, the GL and 1 promoters share several transcription factor binding sites, namely, a Stat6 site, a bZip site, and two ( promoter) or three (1 promoter) NF-B sites. The NF-B binding sites of both promoters were shown previously to be essential for expression and for CD40 inducibility in M12.4.1 cells. We now demonstrate that the affinity of Stat6 for the 1 and promoters differs. In addition, different transcription factors bind the bZip elements adjacent to the Stat6 sites in the two promoters. By exchanging DNA sequences between these two promoters, we determined that the differences in Stat6 binding affinity and bZip binding proteins appear to explain why the promoter is much more responsive to IL-4 and the combination of IL-4 and CD40L stimulation than is the 1 promoter.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Comparison of the GL 1 and promoters

Switching to IgG1 and IgE are differentially regulated, although both isotypes are induced by IL-4 and are T dependent. Previous reports indicate that the mouse GL 1 and transcripts, which are required to direct class switch recombination to a particular S region and thereby a particular C_H gene, are differentially regulated (25, 27, 28). In this manuscript, we attempt to dissect the mechanism for this differential regulation by comparing the regulation of the promoters for GL 1 and transcripts. Promoter constructs consisting of elements of the IL-4-responsive region of the promoter substituted for the comparable region of the 1 promoter and vice-versa were assayed in transient reporter gene experiments. Our results demonstrate that the IL-4-responsive elements within the promoters for GL 1 and differ so that the IL-4-responsive element is more inducible by IL-4 and the combination of CD40L and IL-4, whereas the other regions of the 1 promoter have greater activity. Experiments in which we altered the positions of the Stat6 and bZip elements in the GL 1 promoter to mimic their positions in the GL promoter demonstrated that the elements themselves rather than their different positions within the promoters account for the differences in transcriptional regulation.

Both promoters contain a binding site for Stat6, a transcription factor that is activated by Jak kinases in response to IL-4 signaling (60, 61). However, the relative affinities of the and the 1 Stat6 sites are 10:1, as assayed by competition EMSA. Adjacent to or overlapping with the Stat6 sites in both promoters is a binding site for a bZip protein. In the GL promoter, this site binds AP-1 transcription factors, specifically JunD and FosB in nuclear extracts from activated splenic B cells (32). Mutation of the AP-1 site eliminates both IL-4 and CD40L inducibility and basal expression (32, 36, 38). AP-1 DNA binding activity is inducible in splenic B cells by CD40L, LPS, or by cross-linking surface IgG (32, 62, 63).

The bZip site of the 1 promoter matches a consensus site for C/EBP(NF-IL-6), T(T/G)NNGNAA(T/G) (64), and also matches the optimal binding site for ATF2 (TGACGT(A/C)A), except at position 4 (65, 66). Different members of the ATF/CREB family have different preferred binding sites, as shown by selection of sites from random pools of oligonucleotides (67). Although splenic B and M12.4.1 cells have other ATF proteins (Ref. 54 ; Fig. 4C), ATF-2 binds preferentially at the 1 site.

Unlike the AP-1 site in the promoter, which is essential for induction and for any expression of the promoter, the 1 ATF2 site is not essential for induction of the promoter by a combination of CD40L and IL-4 in M12.4.1 cells or by PMA and IL-4 in A20.3 cells (Fig. 2, A and B). However, the ATF2/C/EBP site is important for overall activity of the promoter, because mutation of the element caused a 2- or 5-fold reduction in activity in M12.4.1 or A20.3 cells, respectively. ATF2 binding is constitutive in these B cell lines, which may explain why its binding site does not contribute to promoter induction in transient reporter assays. It is possible that because ATF2 is inducible in splenic B cells by CD40L, LPS, or by anti- dextran, in vivo it may be important for induction of the promoter. By contrast, it should be noted that mutation of the AP-1 site has a profound effect on the GL promoter, even in cells in which very low levels of AP-1 binding activity is detected (32). Thus, it is clear that the promoter depends much more on the AP-1 site than the 1 promoter depends on the ATF2 site.

Experiments in which the (Stat6 + AP-1) sites are substituted for the comparable 1(Stat6 + ATF2) sites resulted in a promoter that is highly inducible and is much more active than the wild-type GL promoter. In addition to demonstrating that the Stat6 + AP-1 sites of the GL promoter confer more inducibility than the 1(Stat6 + ATF2) elements, these data demonstrate that sequences in the 1 promoter flanking the Stat6/ATF2 sites are much more important for activity of the GL 1 promoter than are comparable regions of the promoter. The latter conclusion is consistent with previous reporter gene experiments in which the effects of linker scanning mutations across the 1 and promoters were examined. It was found that several different mutations within the 1 promoter, both 5' and 3' to the IL-4-responsive region greatly decrease activity and inducibility (33). By contrast, linker scanning mutations across the mouse GL promoter revealed only two essential elements (NF-B sites) and two elements in which mutation partially reduced activity (a B cell-specific activator protein/Pax5 site and an undefined site; Ref. 36, 38 , and 68). The high degree of dependence of the GL promoter on IL-4 for activity should be adaptive in preventing promiscuous production of IgE. The very low levels of IgE in serum and the low numbers of IgE⁺ cells in vivo are consistent with this stringent regulation of GL transcripts. Furthermore, the more promiscuous expression of IgG1 appears adaptive because this Ab can interact with several effector mechanisms to control and eliminate pathogens.

Activation of AP-1 and ATF2

It is unclear whether the fact that AP-1 is more transiently induced than ATF2 is important for the differential regulation of the and 1 promoters. Although both AP-1 and ATF2 are activated in splenic B cells treated with CD40L, LPS, or anti-Ig, AP-1 activity is expressed much more transiently. AP-1 binding activity is induced by 2 h of treatment with CD40L, is maximal at 4 h, and returns to basal levels between 24 and 48 h (32). By contrast, ATF2 binding activity remains elevated for at least 96 h in splenic B cells activated by LPS or anti-IgD (54). Although one could hypothesize that maintenance of ATF2 activity would help to maintain GL 1 transcription over a longer time period than transcription, near maximal levels of both transcripts are sustained for 3–4 days in splenic B cells treated with LPS+IL-4 in culture (27, 69, 70, 71).

It is possible that AP-1 only needs to be transiently induced because it attracts the histone acetyl transferase, p300/CBP (72, 73), which is responsible for remodeling nucleosomes and which may remain bound to the GL promoter after AP-1 levels are reduced. By contrast, although ATF2 also binds p300 (74), it itself has histone acetyl transferase activity (75). Perhaps its binding must be maintained for optimal active chromatin structure.

Signaling via the Ag receptor or via CD40 in human B cells activates all three mitogen-activated protein kinase pathways, i.e., c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38 mitogen-activated kinase kinases (66, 76, 77, 78, 79), and ATF2 and AP-1 are differentially activated by these pathways. Signaling via the Ag receptor or by CD40 induces both phosphorylation and transcriptional activity of both ATF2 and c-Jun (77). Therefore, the large increase in DNA binding activity of ATF2 that we observed in nuclear extracts from activated splenic B cells may be attributable to induced phosphorylation (67). It is also possible, and not mutually exclusive, that binding activity is regulated by interaction with other proteins, e.g., Rb (80) and p300 (74).

C/EBP and C/EBP inhibit transcription from the GL 1 promoter

C/EBP or both C/EBP and C/EBP inhibit transcription from the mouse GL or 1 promoters, respectively, but in neither case does inhibition depend on binding to the bZip site of the promoter (Ref. 32 ; Fig. 6C; C. H. Shen and J.S., unpublished data). C/EBP has been shown to inhibit transcription from B sites and to inhibit the ability of NF-B to bind its cognate site (57, 59). Because NF-B is essential for activity of the GL 1 promoter and for activation of the promoter by CD40 signaling (31, 35), we tested the effect of overexpression of C/EBP on activation of the GL 1 promoter by NF-B RelA/p50. Consistent with the results reported by Stein and Baldwin (57, 59), we observed that C/EBP and the C/EBPbZip domain each inhibit promoter activation by NF-B RelA/p50. Although the mechanism of inhibition of NF-B activity by C/EBP has not been determined, two possibilities were suggested (59). Because C/EBP and NF-B can bind each other in the absence of DNA, C/EBP might be able to squelch the NF-B activity. An alternative is that the heterodimer has a lower affinity for the B site than NF-B itself. Our data do not allow us to determine whether either or both of these mechanisms are occurring.

Support for the physiological role of C/EBP as an inhibitor of GL 1 transcription comes from the finding that mice with a targeted deletion of the C/EBP gene show increased levels of B cells bearing surface IgG1 (81). An effect on cell surface IgE expression was not reported. C/EBP expression is induced by IL-6 and C/EBP in turn activates transcription from the IL-6 gene. IL-6 induces terminal B cell differentiation toward Ab secretion and is found to increase in levels as B cells mature to the plasma cell stage (42, 82). Interestingly, plasma cells do not undergo Ab class switch recombination.

However, the mechanism of inhibition of promoter activity by C/EBP appears to differ, because unlike C/EBP, overexpression of C/EBP does not inhibit induction by CD40L (Fig. 6C). Furthermore, it has never been reported that C/EBP interacts with NF-B. Although overexpressed C/EBP has been shown to inhibit transcription in mouse B cell lines by competing with C/EBP for binding to DNA (55), it is difficult to understand how competition with C/EBP would inhibit the GL 1 promoter. It is clear that there is much left to be understood about C/EBP.

Regulation of other IL-4-responsive genes shows similarities to regulation of the genes for GL Ig 1 and transcripts

One of the two signaling pathways whereby IL-4 exerts its effects results in activation of Stat6, which binds to the promoters of several IL-4-inducible genes (reviewed in Refs. 53 and 83). The IL-4-responsive regions from several genes activated by Stat6 have been studied, and these promoters show several similarities to the mouse GL 1 and promoters. For example, the human GL and 3 promoters and mouse CD23 promoters all contain Stat6 and NF-B binding sites that synergize to induce transcription (84, 85, 86, 87, 88). In addition, the human GL promoter contains a C/EBP site adjacent to the Stat6 element, which is required for transcription of the promoter, and in this case, C/EBP activates transcription via this site (89). Although a C/EBP site has not been identified in the human 3 promoter, cotransfection of an expression plasmid for C/EBP, but not C/EBP, synergistically induced transcription with Stat6 and NF-B (88). The available data suggest that Stat6 does not by itself interact with the basal transcriptional machinery, but instead cooperates with other factors, including members of the bZip and NF-B families, to effectively induce transcription in response to IL-4.

	Acknowledgments

 
We thank Drs. Phyllis LuValle (University of Calgary) for ATF2 expression plasmids, Cathy Cooper (University of Massachusetts Medical School) for C/EBP expression and reporter plasmids, Cliff Snapper (Uniformed Services University of the Health Sciences MD) for anti- dextran, and William E. Paul (National Institutes of Health) for supernatant containing recombinant baculovirus mouse IL-4, and Sean Bradley and Carol Schrader, (University of Massachusetts Medical School) for helpful advice and reagents.

	Footnotes

 
¹ This work was supported by National Institutes of Health Grant AI42108 (to J.S.). The contents of the paper are solely the responsibility of the authors and do not necessarily represent the official views of the National Institute of Allergy and Immunology.

² Address correspondence and reprint requests to Dr. Janet Stavnezer, Department of Molecular Genetics and Microbiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester MA 01655-0122. E-mail address: Janet.Stavnezer{at}umassmed.edu

³ Abbreviations used in this paper: GL, germline; L, ligand; bZip, basic region leucine zipper; CS, consensus; Oct, octamer-binding protein; -gal, -galactosidase; ATF, activating transcription factor.

Received for publication January 29, 2001. Accepted for publication June 5, 2001.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Stavnezer, J.. 1996. Antibody class switching. F. Dixon, ed. In Advances in Immunology Vol. 61:79. Academic Press, San Diego, CA. [Medline]
2. Stavnezer, J.. 1996. Immunoglobulin class switching. Curr. Opin. Immunol. 8:199.[Medline]
3. Snapper, C. M., F. D. Finkelman. 1998. Immunoglobulin class switching. W. E. Paul, ed. Fundamental Immunology 831. Lippincott-Raven, Philadelphia.
4. Davis, M. M., K. Calame, P. W. Early, D. L. Livant, R. Joho, I. L. Weissman, L. Hood. 1980. An immunoglobulin heavy-chain gene is formed by at least two recombinational events. Nature 283:733.[Medline]
5. Kataoka, T., T. Miyata, T. Honjo. 1981. Repetitive sequences in class-switch recombination regions of immunoglobulin heavy chain genes. Cell 23:357.[Medline]
6. Jung, S., K. Rajewsky, A. Radbruch. 1993. Shutdown of class switch recombination by deletion of a switch region control element. Science 259:984.[Abstract]
7. Zhang, J., A. Bottaro, S. Li, V. Stewart, F. W. Alt. 1993. A selective defect in IgG2b switching as a result of targeted mutation of the I2b promoter and exon. EMBO J. 12:3529.[Medline]
8. Bottaro, A., R. Lansford, L. Xu, J. Zhang, P. Rothman, F. Alt. 1994. I region transcription (per se) promotes basal IgE class switch recombination but additional factors regulate the efficiency of the process. EMBO J. 13:665.[Medline]
9. Lorenz, M., S. Jung, A. Radbruch. 1995. Switch transcripts in immunoglobulin class switching. Science 267:1825.[Abstract/Free Full Text]
10. Hein, K., M. G. O. Lorenz, G. Siebenkotten, K. Petry, R. Christine, A. Radbruch. 1998. Processing of switch transcripts is required for targeting of antibody class switch recombination. J. Exp. Med. 188:2369.[Abstract/Free Full Text]
11. King, C. L., J. Xianli, I. Malhotra, S. Liu, A. A. F. Mahmoud, H. C. Oettgen. 1997. Mice with a targeted deletion of the IgE gene have increased worm burdens and reduced granulomatous inflammation following primary infection with Schistosoma mansoni. J. Immunol. 158:294.[Abstract]
12. Coffman, R. L., B. W. P. Seymour, D. A. Lebman, D. D. Hiraki, J. A. Christiansen, B. Shrader, H. M. Cherwinski, H. F. J. Savelkoul, F. D. Finkelman, M. W. Bond, T. R. Mossman. 1988. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102:5.[Medline]
13. Bergstedt-Lindqvist, S., H.-B. Moon, U. Persson, G. Moller, C. Heusser, E. Severinson. 1988. Interleukin 4 instructs uncommitted B lymphocytes to switch to IgG1 and IgE. Eur. J. Immunol. 18:1073.[Medline]
14. Noelle, R. J., M. Roy, D. M. Shepherd, I. Stamenkovic, J. A. Ledbetter, A. Aruffo. 1992. A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc. Natl. Acad. Sci. USA 89:6550.[Abstract/Free Full Text]
15. Lane, P., T. Brocker, S. Hubele, E. Padovan, A. Lanzavecchia, F. McConnell. 1993. Soluble CD40 ligand can replace the normal T cell-derived CD40 ligand signal to B cells in T cell-dependent activation. J. Exp. Med. 177:1209.[Abstract/Free Full Text]
16. Fanslow, W. C., D. M. Anderson, K. H. Grabstein, E. A. Clark, D. Cosman, R. J. Armitage. 1992. Soluble forms of CD40 inhibit biologic responses of human B cells. J. Immunol. 149:655.[Abstract]
17. Snapper, C. M., M. R. Kehry, B. E. Castle, J. J. Mond. 1995. Multivalent, but not divalent, antigen receptor cross-linkers synergize with CD40 ligand for induction of Ig synthesis and class switching in normal murine B cells. J. Immunol. 154:1177.[Abstract]
18. Strom, L., J. Laurencikiene, A. Miskiniene, E. Severinson. 1999. Characterization of CD40-dependent immunoglobulin class switching. Scand. J. Immunol. 49:523.[Medline]
19. Jabara, H. H., S. M. Fu, R. S. Geha, D. Vercelli. 1990. CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J. Exp. Med. 172:1861.[Abstract/Free Full Text]
20. Gascan, H., J.-F. Gauchat, G. Aversa, P. van-Vlasselaer, J. E. De-Vries. 1991. Anti-CD40 monoclonal antibodies or CD4⁺ T cell clones and IL-4 induce IgG4 and IgE switching in purified human B cells via different signaling pathways. J. Immunol. 147:8.[Abstract]
21. Kühn, R., K. Rajewsky, W. Müller. 1991. Generation and analysis of interleukin-4 deficient mice. Science 254:707.[Abstract/Free Full Text]
22. Kopf, M., G. LeGros, M. Bachmann, M. C. Lamers, H. Bluethmann, G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362:245.[Medline]
23. VonderWeid, T., M. Kopf, G. Kohler, J. Langhorne. 1994. The immune response to Plasmodium chabaudi malaria in interleukin-4-deficient mice. Eur. J. Immunol. 24:2285.[Medline]
24. Noben-Trauth, N., P. Kropf, I. Muller. 1996. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271:987.[Abstract]
25. Stavnezer, J., G. Radcliffe, Y.-C. Lin, J. Nieutupski, L. Berggren, R. Sitia, E. Severinson. 1988. Immunoglobulin heavy-chain switching may be directed by prior induction of transcripts from constant-region genes. Proc. Natl. Acad. Sci. USA 85:7704.[Abstract/Free Full Text]
26. Rothman, P., S. Lutzker, W. Cook, R. Coffman, F. W. Alt. 1988. Mitogen plus interleukin 4 induction of C transcripts in B lymphoid cells. J. Exp. Med. 168:2385.[Abstract/Free Full Text]
27. Severinson, E., C. Fernandez, J. Stavnezer. 1990. Induction of germ-line immunoglobulin heavy chain transcripts by mitogens and interleukins prior to switch recombination. Eur. J. Immunol. 20:1079.[Medline]
28. Warren, W. D., M. T. Berton. 1995. Induction of germline 1 and Ig gene expression in murine B cells: interleukin 4 and the CD40 ligand-CD40 interaction provide distinct but synergistic signals. J. Immunol. 155:5637.[Abstract]
29. Elenich, L. A., C. S. Ford, J. T. Collins, W. A. Dunnick. 1997. 1 Heavy chain transgenes are responsive to IFN- repression and CD40 ligation. J. Immunol. 158:4564.[Abstract]
30. Ferlin, W. G., E. Severinson, L. Strom, A. W. Heath, R. L. Coffman, D. A. Ferrick, M. C. Howard. 1996. CD40 signaling induces interleukin-4-independent IgE switching in vivo. Eur. J. Immunol. 26:2911.[Medline]
31. Lin, S.-C., H. H. Wortis, J. Stavnezer. 1998. The ability of CD40L, but not LPS, to initiate immunoglobulin switching to IgG1 is explained by differential induction of NF-B/Rel proteins. Mol. Cell. Biol. 18:5523.[Abstract/Free Full Text]
32. Shen, C. H., J. Stavnezer. 2001. Activation of the mouse Ig germline promoter by IL-4 is dependent on AP-1 transcription factors. J. Immunol. 166:411.[Abstract/Free Full Text]
33. Xu, M., J. Stavnezer. 1992. Regulation of transcription of immunoglobulin germ-line 1 RNA: analysis of the promoter/enhancer. EMBO J. 11:145.[Medline]
34. Zelazowski, P., J. T. Collins, W. Dunnick, C. M. Snapper. 1995. Antigen receptor cross-linking differentially regulates germ-line C_H ribonucleic acid expression in murine B cells. J. Immunol. 154:1223.[Abstract]
35. Lin, S. C., J. Stavnezer. 1996. Activation of NF-B/Rel by CD40 engagement induces the mouse germline immunoglobulin C1 promoter. Mol. Cell. Biol. 16:4591.[Abstract]
36. Iciek, L. A., S. A. Delphin, J. Stavnezer. 1997. CD40 cross-linking induces Ig germline transcripts in B cells via activation with NF-B: synergy with IL-4 induction. J. Immunol. 158:4769.[Abstract]
37. Warren, W. D., K. L. Roberts, L. A. Linehan, M. T. Berton. 1999. Regulation of the germline immunoglobulin C1 promoter by CD40 ligand and IL-4: dual role for tandem NF-B binding sites. Mol. Immunol. 36:31.[Medline]
38. Delphin, S. A., J. Stavnezer. 1995. Characterization of an IL-4 responsive region in the immunoglobulin heavy chain promoter: regulation by NF-IL4, a C/EBP family member and NF-B/p50. J. Exp. Med. 181:181.[Abstract/Free Full Text]
39. Schrader, C. E., W. Edelmann, R. Kucherlapati, J. Stavnezer. 1999. Reduced isotype switching in splenic B cells from mice deficient in mismatch repair enzymes. J. Exp. Med. 190:323.[Abstract/Free Full Text]
40. Watson, C., U. Atasoy, J. Ohara, W. E. Paul. 1990. Production of recombinant murine lymphokines in a baculovirus expression system. FASEB J. 4:1740. (Abstr.).
41. Nordeen, S. K.. 1988. Luciferase reporter gene vectors for analysis of promoters and enhancers. BioTechniques 6:454.[Medline]
42. Cooper, C. L., A. L. Berrier, C. Roman, K. L. Calame. 1994. Limited expression of C/EBP family proteins during B lymphocyte development. J. Immunol. 153:5049.[Abstract]
43. Beier, F., R. J. Lee, A. C. Taylor, R. G. Pestell, P. LuValle. 1999. Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes. Proc. Natl. Acad. Sci. USA 96:1433.[Abstract/Free Full Text]
44. Chevray, P. M., D. Nathans. 1992. Protein interaction cloning in yeast: identification of mammalian proteins that react with the leucine zipper of Jun. Proc. Natl. Acad. Sci. USA 89:5789.[Abstract/Free Full Text]
45. Tavares, D., K. Tully, P. R. Dobner. 1999. Sequences required for induction of neurotensin receptor gene expression during neuronal differentiation of N1E-115 neuroblastoma cells. J. Biol. Chem. 274:30066.[Abstract/Free Full Text]
46. Miner, J. N., K. R. Yamamoto. 1992. The basic region of AP-1 specifies glucocorticoid receptor activity at a composite response element. Genes Dev. 6:2491.[Abstract/Free Full Text]
47. Kohler, I., E. P. Rieber. 1993. Allergy-associated I and Fc receptor II (CD23b) genes activated via binding of an interleukin-4-induced transcription factor to a novel responsive element. Eur. J. Immunol. 23:3066.[Medline]
48. Hai, T., T. Curran. 1991. Fos/Jun and ATF/CREB cross-family dimerization alters DNA binding specificity. Proc. Natl. Acad. Sci. USA 88:3720.[Abstract/Free Full Text]
49. Hsu, W., T. K. Kerppola, P.-L. Chen, T. Curran, S. Chen-Kiang. 1994. Fos and Jun repress transcription activation by NF-IL6 through association at the basic zipper region. Mol. Cell. Biol. 14:268.[Abstract/Free Full Text]
50. Kotanides, H., N. C. Reich. 1993. Requirement of tyrosine phosphorylation for rapid activation of a DNA binding factor by IL-4. Science 262:1265.[Abstract/Free Full Text]
51. Berton, M. T., L. A. Linehan. 1995. IL-4 activates a latent DNA-binding factor that binds a shared IFN- and IL-4 response element present in the germ-line 1 Ig promoter. J. Immunol. 154:4513.[Abstract]
52. Lundgren, M., C. Larrson, A. Femino, M. Xu, J. Stavnezer, E. Severinson. 1994. Activation of the Ig germ-line 1 promoter: involvement of C/EBP transcription factors and their possible interaction with a NF-IL4 site. J. Immunol. 153:2983.[Abstract]
53. Ehret, G. B., P. Reichenbach, U. Schindler, C. M. Horvath, S. Fritz, M. Nabholz, P. Bucher. 2001. DNA binding specificity of different STAT proteins: comparison of in vitro specificity with natural target sites. J. Biol. Chem. 276:6675.[Abstract/Free Full Text]
54. Feuerstein, N., R. Firestein, N. Aiyar, X. He, D. Murasko, V. Cristofalo. 1996. Late induction of CREB/ATF binding and a concomitant increase in cAMP levels in T and B lymphocytes stimulated via the antigen receptor. J. Immunol. 156:4582.[Abstract]
55. Cooper, C., A. Henderson, S. Artandi, N. Avitahl, K. Calame. 1995. Ig/EBP (C/EBP) is a transdominant negative inhibitor of C/EBP family transcriptional activators. Nucleic Acids Res. 23:4371.[Abstract/Free Full Text]
56. LeClair, K. P., M. A. Blanar, P. A. Sharp. 1992. The p50 subunit of NF-B associates with NF-IL6 transcription factor. Proc. Natl. Acad. Sci. USA 89:8145.[Abstract/Free Full Text]
57. Stein, B., Jr A. S. Baldwin. 1993. Distinct mechanisms for regulation of the interleukin-8 gene involve synergism and cooperativity between C/EBP and NF-B. Mol. Cell. Biol. 13:7191.[Abstract/Free Full Text]
58. Matsusaka, T., K. Fujikawa, Y. Nishio, N. Mukaida, K. Matsushima., T. Kishimoto, S. Akira. 1993. Transcription factors NF-IL6 and NF-B synergistically activate transcription of the inflammatory cytokines, IL-6 and IL-8. Proc. Natl. Acad. Sci. USA 90:10193.[Abstract/Free Full Text]
59. Stein, B., P. C. Cogswell, Jr A. S. Baldwin. 1993. Functional and physical associations between NF-B and C/EBP family members: a Rel domain-bZIP interaction. Mol. Cell. Biol. 13:3964.[Abstract/Free Full Text]
60. Hou, J., U. Schindler, W. J. Henzel, T. C. Ho, M. Brasseur, S. L. McKnight. 1994. An interleukin-4-induced transcription factor: IL-4 Stat. Science 265:1701.[Abstract/Free Full Text]
61. Quelle, F. W., K. Shimoda, W. Thierfelder, C. Fischer, A. Kim, S. M. Ruben, J. L. Cleveland, J. H. Pierce, A. D. Keegan, K. Nelms, et al 1995. Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol. Cell. Biol. 15:3336.[Abstract]
62. Francis, D. A., J. G. Karras, X. Y. Ke, R. Sen, T. L. Rothstein. 1995. Induction of the transcription factors NF-B, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int. Immunol. 7:151.[Abstract/Free Full Text]
63. Huo, L., T. L. Rothstein. 1995. Receptor specific induction of individual AP-1 components in B lymphocytes. J. Immunol. 154:3300.[Abstract]
64. Akira, S., H. Isshiki, T. Sugita, O. Tanabe, S. Kinoshita, Y. Nishio, T. Nakajima, T. Hirano, T. Kishimoto. 1990. A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J. 9:1897.[Medline]
65. Benbrook, D. M., N. C. Jones. 1994. Different binding specificities and transactivation of variant CREs by CREB complexes. Nucleic Acids Res. 22:1463.[Abstract/Free Full Text]
66. Gupta, S., D. Campbell, B. Derijard, R. J. Davis. 1995. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 267:389.[Abstract/Free Full Text]
67. Li, X. Y., M. R. Green. 1996. Intramolecular inhibition of activating transcription factor-2 function by its DNA-binding domain. Genes Dev. 10:517.[Abstract/Free Full Text]
68. Liao, F., B. Birshtein, M. Busslinger, P. Rothman. 1994. The transcription factor BSAP (NF-HB) is essential for immunoglobulin germ-line transcription. J. Immunol. 152:2904.[Abstract]
69. Berton, M. T., J. W. Uhr, E. Vitetta. 1989. Synthesis of germline 1 immunoglobulin heavy-chain transcripts in resting B cells: induction by interleukin 4 and inhibition by interferon . Proc. Natl. Acad. Sci. USA 86:2829.[Abstract/Free Full Text]
70. Rothman, P., Y.-Y. Chen, S. Lutzker, S. C. Li, V. Stewart, R. Coffman, F. W. Alt. 1990. Structure and expression of germline immunoglobulin heavy chain transcripts: interleukin-4-plus lipopolysaccharide-directed switching to C. Mol. Cell. Biol. 10:1672.[Abstract/Free Full Text]
71. Xu, L., P. Rothman. 1994. IFN- represses germline transcription and subsequently down-regulates switch recombination to . Int. Immunol. 6:515.[Abstract/Free Full Text]
72. Arias, J., A. S. Alberts, P. Brindle, F. X. Claret, T. Smeal, M. Karin, J. Fermisco, M. Montminy. 1994. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. Nature 370:226.[Medline]
73. Horvai, A. E., L. Xu, E. Korzus, G. Brard, D. Kalafus, T.-M. Mullen, M. G. R. D. W. Rose, C. K. Glass. 1997. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad. Sci. USA 94:1074.[Abstract/Free Full Text]
74. Sano, Y., F. Tokitou, P. Dai, T. Maekawa, T. Yamamoto, S. Ishii. 1998. CBP alleviates the intramolecular inhibition of ATF-2 function. J. Biol. Chem. 273:29098.[Abstract/Free Full Text]
75. Kawasaki, H., L. Schiltz, R. Chiu, K. Itakura, K. Taira, Y. Nakatani, K. K. Yokoyama. 2000. ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation. Nature 405:195.[Medline]
76. Livingstone, C., G. Patel, N. Jones. 1995. ATF-2 contains a phosphorylation-dependent transcriptional activation domain. EMBO J. 14:1785.[Medline]
77. Raingeaud, J., A. J. Whitmarsh, T. Barrett, B. Derijard, R. J. Davis. 1996. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol. Cell. Biol. 16:1247.[Abstract]
78. Kim, S. J., S. Wagner, F. Liu, M. A. O’Reilly, P. D. Robbins, M. R. Green. 1992. Retinoblastoma gene product activates expression of the human TGF-2 gene through transcription factor ATF-2. Nature 358:331.[Medline]
79. Robinson, M. J., M. H. Cobb. 1997. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9:180.[Medline]
80. Sakata, N., H. Kawasome, N. Terada, P. Gerwins, G. L. Johnson, E. W. Gelfand. 1999. Differential activation and regulation of mitogen-activated protein kinases through the antigen receptor and CD40 in human B cells: [Published erratum appears in 2000 Eur. J. Immunol. 30:1795.]. Eur. J. Immunol. 29:2999.[Medline]
81. Screpanti, I., L. Romani, P. Musiani, A. Modesti, E. Fattori, D. Lazzaro, C. Sellitto, S. Scarpa, D. Bellavia, G. Lattanzio, et al 1995. Lymphoproliferative disorder and imbalanced T-helper response in C/EBP-deficient mice: [Published erratum appears in 1995 EMBO J. 14:3596.]. EMBO J. 14:1932.[Medline]
82. Hirano, T., S. Akira, T. Taga, T. Kishimoto. 1990. Biological and clinical aspects of interleukin 6. Immunol. Today 11:443.[Medline]
83. Nelms, K., A. D. Keegan, J. Zamorano, J. J. Ryan, W. E. Paul. 1999. The IL-4 receptor: signaling mechanisms and biologic functions. Annu. Rev. Immunol. 17:701.[Medline]
84. Messner, B., A. M. Stutz, B. Albrecht, S. Peiritsch, M. Woisetschlager. 1997. Cooperation of binding sites for STAT6 and NFB/rel in the IL-4-induced up-regulation of the human IgE germline promoter. J. Immunol. 159:3330.[Abstract]
85. Richards, M. L., D. H. Katz. 1997. Analysis of the promoter elements necessary for IL-4 and anti-CD40 antibody induction of murine FcRII (CD23): comparison with the germline promoter. J. Immunol. 158:263.[Abstract]
86. Tinnell, S. B., S. M. Jacobs-Helber, E. Sterneck, S. T. Sawyer, D. H. Conrad. 1998. STAT6, NF-B and C/EBP in CD23 expression and IgE production. Int. Immunol. 10:1529.[Abstract/Free Full Text]
87. Schaffer, A., A. Cerutti, S. Shah, H. Zan, P. Casali. 1999. The evolutionarily conserved sequence upstream of the human Ig heavy chain S3 region is an inducible promoter: synergistic activation by CD40 ligand and IL-4 via cooperative NF- B and STAT-6 binding sites. J. Immunol. 162:5327.[Abstract/Free Full Text]
88. Pan, Q., C. Petit-Frere, J. Stavnezer, L. Hammarstrom. 2000. Regulation of the promoter for human immunoglobulin 3 germ-line transcription and its interaction with the 3' enhancer. Eur. J. Immunol. 30:1019.[Medline]
89. Mikita, T., D. Campbell, P. Wu, K. Williamson, U. Schindler. 1996. Requirements for interleukin-4-induced gene expression and functional characterization of Stat6. Mol. Cell. Biol. 16:5811.[Abstract]

This article has been cited by other articles:

				O. I. Iweala, D. W. Smith, K. S. Matharu, I. Sada-Ovalle, D. D. Nguyen, R. H. DeKruyff, D. T. Umetsu, S. M. Behar, and C. R. Nagler Vaccine-Induced Antibody Isotypes Are Skewed by Impaired CD4 T Cell and Invariant NKT Cell Effector Responses in MyD88-Deficient Mice J. Immunol., August 15, 2009; 183(4): 2252 - 2260. [Abstract] [Full Text] [PDF]

				T. Doi, K. Obayashi, T. Kadowaki, H. Fujii, and S. Koyasu PI3K is a negative regulator of IgE production Int. Immunol., April 1, 2008; 20(4): 499 - 508. [Abstract] [Full Text] [PDF]

				M. E. Munroe, J. L. Arbiser, and G. A. Bishop Honokiol, a Natural Plant Product, Inhibits Inflammatory Signals and Alleviates Inflammatory Arthritis J. Immunol., July 15, 2007; 179(2): 753 - 763. [Abstract] [Full Text] [PDF]

				K. Obayashi, T. Doi, and S. Koyasu Dendritic cells suppress IgE production in B cells Int. Immunol., February 1, 2007; 19(2): 217 - 226. [Abstract] [Full Text] [PDF]

				H.-C. Chen, J. C. Byrd, and N. Muthusamy Differential Role for Cyclic AMP Response Element Binding Protein-1 in Multiple Stages of B Cell Development, Differentiation, and Survival J. Immunol., February 15, 2006; 176(4): 2208 - 2218. [Abstract] [Full Text] [PDF]

				S. C. Fish, D. D. Donaldson, S. J. Goldman, C. M. M. Williams, and M. T. Kasaian IgE Generation and Mast Cell Effector Function in Mice Deficient in IL-4 and IL-13 J. Immunol., June 15, 2005; 174(12): 7716 - 7724. [Abstract] [Full Text] [PDF]

				M. T. Berton, L. A. Linehan, K. R. Wick, and W. A. Dunnick NF-{kappa}B elements associated with the Stat6 site in the germline {gamma}1 immunoglobulin promoter are not necessary for the transcriptional response to CD40 ligand Int. Immunol., December 1, 2004; 16(12): 1741 - 1749. [Abstract] [Full Text] [PDF]

				B. He, N. Raab-Traub, P. Casali, and A. Cerutti EBV-Encoded Latent Membrane Protein 1 Cooperates with BAFF/BLyS and APRIL to Induce T Cell-Independent Ig Heavy Chain Class Switching J. Immunol., November 15, 2003; 171(10): 5215 - 5224. [Abstract] [Full Text] [PDF]

				A. Suto, H. Nakajima, K. Hirose, K. Suzuki, S.-i. Kagami, Y. Seto, A. Hoshimoto, Y. Saito, D. C. Foster, and I. Iwamoto Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cepsilon transcription of IL-4-stimulated B cells Blood, December 15, 2002; 100(13): 4565 - 4573. [Abstract] [Full Text] [PDF]

				L. Ma, H. H. Wortis, and A. L. Kenter Two New Isotype-Specific Switching Activities Detected for Ig Class Switching J. Immunol., March 15, 2002; 168(6): 2835 - 2846. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mao, C.-s. Articles by Stavnezer, J. Search for Related Content PubMed PubMed Citation Articles by Mao, C.-s. Articles by Stavnezer, J.